These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 171564)

  • 1. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W; Kremer GJ; Müller D
    MMW Munch Med Wochenschr; 1975 Oct; 117(44):1783-6. PubMed ID: 171564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
    Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
    MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
    Gaertner U; Johannes KJ
    MMW Munch Med Wochenschr; 1976 Sep; 118(36):1127-30. PubMed ID: 184377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
    MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
    Schwartzkopff W; Zschiedrich M
    Med Klin; 1978 Feb; 73(7):231-9. PubMed ID: 203832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
    Gustafson A
    Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of miskleron in ischemic heart disease with differing types of hyperlipoproteinemias].
    Krivoruchenko IV; Nikul'cheva NG
    Kardiologiia; 1976 Jul; 16(7):71-5. PubMed ID: 185448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ
    Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Different forms of hyperlipoproteinemia in diabetics (author's transl)].
    Vogt N; Englhardt A
    Med Klin; 1975 Nov; 70(46):1871-7. PubMed ID: 171548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P; Schwandt P
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():398-401. PubMed ID: 206058
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
    Koschinsky T; Lenhard P; Gries FA; Vogelberg KH; Wolfram G; Lang PD; Vollmar J
    Med Klin; 1977 Sep; 72(38):1537-43. PubMed ID: 904549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A physician's guide to hyperlipidemia.
    Fredrickson DS
    Mod Concepts Cardiovasc Dis; 1972 Jul; 41(7):31-6. PubMed ID: 4343098
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Familial hyperlipoproteinemia type III].
    Patsch JR; Patsch W; Sailer S; Braunsteiner H
    Dtsch Med Wochenschr; 1976 Oct; 101(44):1612-9. PubMed ID: 185039
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
    Haacke H; Parwaresch MR; Mäder C
    Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interference of clofibrate in metabolic compensation in dyslipidemic diabetics].
    Gatti A; Carletta C
    Clin Ter; 1979 Oct; 91(1):57-65. PubMed ID: 397871
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.